Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |
Biological: Behavioural genetics · Evolutionary psychology · Neuroanatomy · Neurochemistry · Neuroendocrinology · Neuroscience · Psychoneuroimmunology · Physiological Psychology · Psychopharmacology (Index, Outline)
|Syndrome of inappropriate antidiuretic hormone secretion|
|Classification and external resources|
|eMedicine||emerg/784 med/3541 ped/2190|
The syndrome of inappropriate antidiuretic hormone secretion or SIADH (other names: Schwartz-Bartter syndrome, SIAD—syndrome of immoderate antidiuresis) is characterized by excessive release of antidiuretic hormone from the posterior pituitary gland or another source. The result is often dilutional hyponatremia in which the sodium remains normal but total body fluid increases. It was originally described in people with small-cell carcinoma of the lung, but it can be caused by a number of underlying medical conditions. The treatment may consist of fluid intake restriction, various medicines, and management of the underlying cause. SIADH was first described in 1957.
Signs and symptomsEdit
- Muscle aches
- Subtle neurological symptoms i.e.
- Coma from cerebral oedema
Some common causes of SIADH include: Template:Uncited
- Head injury
- Lung cancer (especially small-cell lung cancer, as well as other small-cell malignancies of other organs)
- Guillain-Barré syndrome
- Selective serotonin reuptake inhibitors (SSRIs, a class of antidepressants)
- Methylenedioxymethamphetamine (MDMA, commonly called Ecstasy. SIADH due to taking ecstasy was cited as a factor in the death of Leah Betts)
The normal function of ADH on the kidneys is to control the amount of water reabsorbed by kidney nephrons. ADH acts in the distal portion of the renal tubule (Distal Convoluted Tubule) as well as on the collecting duct and causes the retention of water, but not solute. Hence, ADH activity effectively dilutes the blood (decreasing the concentrations of solutes such as sodium). Template:Uncited
ADH is secreted to prevent water loss in the kidneys. When water is ingested, it is taken up into the circulation and results in a dilution of the plasma. This dilution, otherwise described as a reduction in plasma osmolality, is detected by osmoreceptors in the hypothalamus of the brain and these then switch off the release of ADH. The decreasing concentration of ADH effectively inhibits the aquaporins in the collecting ducts and distal convoluted tubules in the nephrons of the kidney. Hence, less water is reabsorbed, thereby increasing urine output, decreasing urine osmolality, and normalizing blood osmolality.Template:Uncited
In SIADH the release of ADH is not inhibited by a reduction in plasma osmolality when the individual ingests water and the osmolality of the plasma drops. As the main solute of plasma is sodium, this hypoosmolar state is usually detected as a low sodium level on laboratory testing. SIADH is therefore primarily a condition that results in the abnormal handling of water loading and not a problem with excessive solute loss. This is why it is usually treated with fluid (in particular water) restriction. Diuretics may also be given to decrease reabsorption of water, but care must be taken not to correct water imbalances too rapidly.Template:Uncited
This causes dilutional hyponatremia and all the consequences associated with that condition: headache, nausea, vomiting, and confusion may ensue. Severe hyponatremia may cause convulsions or coma.Template:Uncited
The abnormalities underlying type D syndrome of inappropriate antidiuretic hormone hypersecretion concern individuals where vasopressin release and response are normal but where abnormal renal expression and translocation of aquaporin 2, or both are found. It has been suggested that this is due to abnormalities in the secretion of secretin in the brain and that "Secretin as a neurosecretory hormone from the posterior pituitary, therefore, could be the long-sought vasopressin independent mechanism to solve the riddle that has puzzled clinicians and physiologists for decades."
In general, increased ADH causes water retention without extracellular fluid volume expansion and without edema or hypertension. The water retention causes hyponatremia, which is a key feature in SIADH. This is purely a problem of water metabolism with no abnormalities in total body sodium metabolism. Hyponatremia and inappropriately concentrated urine (UOsm >100 mOsm/L) are seen, as well as no signs of edema or hypovolemia. When hyponatremia is severe (sodium <120 mOsm), or acute in onset, symptoms of cerebral edema become prominent (irritability, confusion, seizures, and coma).
Laboratory findings in diagnosis of SIADH include:
- Euvolemic hyponatremia <134 mEq/L, and POsm <275 mOsm/kg OR ( POsm - Serum [Urea]mmol/l < 280 mOsm/kg )
- Urine osmolality >100mOsm/kg of water during hypotonicity
- Urine sodium concentration >40 mEq/L with normal dietary salt intake
- Clinical euvolemia without edema or ascites
- Low blood urea nitrogen (BUN)
- Normal serum creatinine
- Low uric acid
- Normal Acid-Base, K+ balance
- Normal Adrenal, Thyroid function
Management of SIADH includes:
- Treating underlying causes when possible.
- Long-term fluid restriction of 1,200–1,800 mL/day will increase serum sodium through decreasing total body water.
- For very symptomatic patients (severe confusion, convulsions, or coma) hypertonic saline (3%) 1–2 ml/kg IV in 3–4 h should be given.
- Demeclocycline can be used in chronic situations when fluid restrictions are difficult to maintain; demeclocycline is the most potent inhibitor of Vasopressin (ADH/AVP) action. However, demeclocycline has a 2–3 day delay in onset with extensive side effect profile, including skin photosensitivity, and nephrotoxicity.
- Urea: oral daily ingestion has shown favorable long-term results with protective effects in myelinosis and brain damage. Limitations noted to be undesirable taste and is contraindicated in patients with cirrhosis to avoid initiation or potentiation of hepatic encephalopathy.
- Conivaptan – an antagonist of both V1A and V2 vasopressin receptors. Its indications are "treatment of euvolemic hyponatremia (e.g. the syndrome of inappropriate secretion of antidiuretic hormone, or in the setting of hypothyroidism, adrenal insufficiency, pulmonary disorders, etc.) in hospitalized patients.". Conivaptan, however, is only available as a parenteral preparation.
- Tolvaptan – an antagonist of the V2 vasopressin receptor. A randomized controlled trial showed tolvaptan is able to raise serum sodium in patients with euvolemic or hypervolemic hyponatremia in 2 different tests. Combined analysis of the 2 trials showed an improvement in hyponatremia in both the short term (primary sodium change in average AUC: 3.62+/- 2.68 and 4.35 +/-2.87) and long term with long term maintenance (primary sodium change in average AUC: 6.22 +/- 4.22 and 6.20 +/- 4.92), at 4 days and 30 days, respectively. Tolvaptan's side effect profile is minimal. Discontinuation of the Tolvaptan showed return of hyponatremia to control values at their respective time frames.
No head to head study is currently available to quantify and compare the relative efficacies of V2 vasopressin receptor antagonists with demeclocycline or other treatment options.Template:Uncited
Care must be taken when correcting hyponatremia. A rapid rise in the sodium level may cause central pontine myelinolysis. Avoid correction by more than 12 mEq/L/day. Initial treatment with hypertonic saline may abruptly lead to a rapid dilute diuresis and fall in ADH. Rapid diuresis may lead to over-rapid rise in serum sodium, and should be managed with extreme care.Template:Uncited
The condition was first described by researchers from Boston, Massachusetts and Bethesda, Maryland (including Dr Frederic Bartter) in two patients with lung cancer. Criteria were developed by Schwartz and Bartter in 1967 and have remained essentially unchanged since then. The condition is occasionally referred to by the names of the authors of the first report - Schwartz-Bartter syndrome.
- ↑ 1.0 1.1 Chu JY, Lee LT, Lai CH, Vaudry H, Chan YS, Yung WH, Chow BK.(2009). Secretin as a neurohypophysial factor regulating body water homeostasis. Proceedings of the National Academy of Sciences USA, 106:15961–15966. DOI:10.1073/pnas.0903695106
- ↑ Onitilo AA, Kio E, Doi SA. Tumor-related hyponatremia. Clin Med Res. 2007 Dec;5(4):228-37.
- ↑ Adrogué HJ, Madias NE. Hyponatremia. N Engl J Med. 2000 May 25;342(21):1581-9
- ↑ DOI:10.1007/978-3-540-79565-0_40
- ↑ 5.0 5.1 5.2 Zietse, Robert, van der Lubbe N, Hoorn E (2009). Current and Future Treatment Options in SIADH. Nephrology Dialysis Transplantation 2 [Suppl 3] (Suppl_3): iii12–iii19.
- ↑ Vaprisol (conivaptan hydrochloride) Liquid [Astellas Pharma US, Inc.]. URL accessed on 2007-06-08.
- ↑ Schrier RW, Gross P, Gheorghiade M, et al. (2006). Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N. Engl. J. Med. 355 (20): 2099–112.
- ↑ Ashrafian H, Davey P (2001). A review of the causes of central pontine myelinosis: yet another apoptotic illness?. Eur. J. Neurol. 8 (2): 103–9.
- ↑ Schwarts WB, Bennett W, Curelop S, Bartter FC (1957). A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am. J. Med. 23 (4): 529–42. reproduced in Schwartz WB, Bennett W, Curelop S, Bartter FC (1 December 2001). A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. 1957. J. Am. Soc. Nephrol. 12 (12): 2860–70.
- ↑ Bartter FC, Schwartz WB (1967). The syndrome of inappropriate secretion of antidiuretic hormone. Am. J. Med. 42 (5): 790–806.
- ↑ Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH (2007). Hyponatremia treatment guidelines 2007: expert panel recommendations. Am. J. Med. 120 (11 Suppl 1): S1–21.
- ↑ Who Named It synd/2327
Endocrine pathology of psychological interest (E00-35)
thyroid Hypothyroidism (Iodine deficiency, Cretinism, Congenital hypothyroidism, Goitre) - Hyperthyroidism (Graves-Basedow disease, Toxic multinodular goitre) - Thyroiditis (De Quervain's thyroiditis, Hashimoto's thyroiditis)
Urinary system - Pathology - Nephrology (N00-N39, 580-599)
|Diseases of the glomerulus||
Glomerulonephritis - Focal segmental glomerulosclerosis - Membranoproliferative glomerulonephritis - Membranous glomerulonephritis - Nephritic syndrome - Post-streptococcal glomerulonephritis - Nephrotic syndrome (Minimal change disease) - IgA nephropathy - Lupus nephritis - Diabetic nephropathy - Rapidly progressive glomerulonephritis
|Tubulointerstitial diseases of the kidney|
| Diseases of the renal tubule and|
other disorders of kidney and ureter
| Other diseases and|
disorders of urinary system
|Tumors of the kidney|
|This page uses Creative Commons Licensed content from Wikipedia (view authors).|